Birchview Capital’s Pacific Biosciences PACB Stock Holding History

Birchview Capital’s Portfolio PACB Stock Details PACB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.27M	Sell	1,350,000 -150,000	-10%	-$218K	1.06%	26
2026 Q1	$1.98M	Buy	1,500,000 +1,000,000	+200%	+$1.79M	1.13%	26
2025 Q4	$935K	Hold	500,000	–	–	0.55%	41
2025 Q3	$640K	Buy	500,000 +100,000	+25%	+$135K	0.48%	46
2025 Q2	$496K	Buy	+400,000	New	+$462K	0.49%	44
2017 Q3	–	Sell	-27,000	Closed	-$96K	–	42
2017 Q2	$96K	Hold	27,000	–	–	0.05%	38
2017 Q1	$140K	Hold	27,000	–	–	0.08%	39
2016 Q4	$103K	Hold	27,000	–	–	0.06%	41
2016 Q3	$242K	Hold	27,000	–	–	0.14%	33
2016 Q2	$190K	Hold	27,000	–	–	0.14%	34
2016 Q1	$230K	Buy	+27,000	New	+$266K	0.16%	33

Other funds holding PACB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return

NAMA

Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Birchview Capital's PACB Position: Q2 2026 in Review

Birchview Capital reduced its Pacific Biosciences (PACB) stake by 10% in Q2 2026, selling an estimated $218K and leaving 1,350,000 shares worth $2.27M. The position accounts for 1.06% of the portfolio, ranked #26.

Birchview Capital first reported a position in PACB in Q1 2016 and has held it in 11 quarters since. 223 funds tracked by Wall St. Rank hold PACB as of Q2 2026.

Birchview Capital held 1,350,000 shares of Pacific Biosciences worth $2.27M as of Q2 2026.
Birchview Capital sold 150,000 Pacific Biosciences shares in Q2 2026, an estimated $218K.
Pacific Biosciences made up 1.06% of Birchview Capital's portfolio in Q2 2026, its #26 holding.
Birchview Capital first reported a position in Pacific Biosciences in Q1 2016 and has held it in 11 quarters since.
223 funds tracked by Wall St. Rank held Pacific Biosciences as of Q2 2026.

Based on Birchview Capital's 13F filing for Q2 2026, filed 14 Aug 2026.